Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease.

Sise ME, Chute DF, Oppong Y, Davis MI, Long JD, Silva ST, Rusibamayila N, Jean-Francois D, Raji S, Zhao S, Thadhani R, Chung RT.

Kidney Int. 2019 May 15. pii: S0085-2538(19)30508-3. doi: 10.1016/j.kint.2019.04.030. [Epub ahead of print]

PMID:
31337501
2.

High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.

Wang S, Hwang EE, Guha R, O'Neill AF, Melong N, Veinotte CJ, Conway Saur A, Wuerthele K, Shen M, McKnight C, Alexe G, Lemieux ME, Wang A, Hughes E, Xu X, Boxer MB, Hall MD, Kung A, Berman JN, Davis MI, Stegmaier K, Crompton BD.

Clin Cancer Res. 2019 Jul 15;25(14):4552-4566. doi: 10.1158/1078-0432.CCR-17-0375. Epub 2019 Apr 12.

PMID:
30979745
3.

Polycythemia Vera Presenting as Cardiac Arrest: Novel Management Strategies.

Davis MI, Courtney BK, Cohen G, Poon S, Madan M.

Case Rep Cardiol. 2019 Jan 22;2019:9656387. doi: 10.1155/2019/9656387. eCollection 2019.

4.

Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.

Iniguez AB, Alexe G, Wang EJ, Roti G, Patel S, Chen L, Kitara S, Conway A, Robichaud AL, Stolte B, Bandopadhayay P, Goodale A, Pantel S, Lee Y, Cheff DM, Hall MD, Guha R, Davis MI, Menard M, Nasholm N, Weiss WA, Qi J, Beroukhim R, Piccioni F, Johannessen C, Stegmaier K.

Cancer Cell. 2018 Dec 10;34(6):922-938.e7. doi: 10.1016/j.ccell.2018.11.005.

PMID:
30537514
5.

A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.

Guenther LM, Dharia NV, Ross L, Conway A, Robichaud AL, Catlett JL 2nd, Wechsler CS, Frank ES, Goodale A, Church AJ, Tseng YY, Guha R, McKnight CG, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F, Stegmaier K.

Clin Cancer Res. 2019 Feb 15;25(4):1343-1357. doi: 10.1158/1078-0432.CCR-18-0372. Epub 2018 Nov 5.

6.

Interference with Fluorescence and Absorbance.

Simeonov A, Davis MI.

In: Sittampalam GS, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Coussens NP, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kahl SD, Kales SC, Kirshner S, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2015 Dec 7 [updated 2018 Jul 1].

7.

The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra.

Davis MI, Crittenden JR, Feng AY, Kupferschmidt DA, Naydenov A, Stella N, Graybiel AM, Lovinger DM.

PLoS One. 2018 Feb 21;13(2):e0191436. doi: 10.1371/journal.pone.0191436. eCollection 2018.

8.

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.

Urban DJ, Martinez NJ, Davis MI, Brimacombe KR, Cheff DM, Lee TD, Henderson MJ, Titus SA, Pragani R, Rohde JM, Liu L, Fang Y, Karavadhi S, Shah P, Lee OW, Wang A, McIver A, Zheng H, Wang X, Xu X, Jadhav A, Simeonov A, Shen M, Boxer MB, Hall MD.

Sci Rep. 2017 Oct 6;7(1):12758. doi: 10.1038/s41598-017-12630-x.

9.

When and how can nephrologists treat hepatitis C virus infection in dialysis patients?

Davis MI, Chute DF, Chung RT, Sise ME.

Semin Dial. 2018 Jan;31(1):26-36. doi: 10.1111/sdi.12650. Epub 2017 Sep 18. Review.

PMID:
28925068
10.

Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.

Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ.

Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12.

11.

Aldehyde dehydrogenase 1-positive nigrostriatal dopaminergic fibers exhibit distinct projection pattern and dopamine release dynamics at mouse dorsal striatum.

Sgobio C, Wu J, Zheng W, Chen X, Pan J, Salinas AG, Davis MI, Lovinger DM, Cai H.

Sci Rep. 2017 Jul 13;7(1):5283. doi: 10.1038/s41598-017-05598-1.

12.

mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination Screening.

Chen L, Wilson K, Goldlust I, Mott BT, Eastman R, Davis MI, Zhang X, McKnight C, Klumpp-Thomas C, Shinn P, Simmons J, Gormally M, Michael S, Thomas CJ, Ferrer M, Guha R.

Sci Rep. 2016 Nov 24;6:37741. doi: 10.1038/srep37741.

13.

Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.

Davis MI, Pragani R, Fox JT, Shen M, Parmar K, Gaudiano EF, Liu L, Tanega C, McGee L, Hall MD, McKnight C, Shinn P, Nelson H, Chattopadhyay D, D'Andrea AD, Auld DS, DeLucas LJ, Li Z, Boxer MB, Simeonov A.

J Biol Chem. 2016 Nov 18;291(47):24628-24640. Epub 2016 Sep 28.

14.

Identification of Novel Plasmodium falciparum Hexokinase Inhibitors with Antiparasitic Activity.

Davis MI, Patrick SL, Blanding WM, Dwivedi V, Suryadi J, Golden JE, Coussens NP, Lee OW, Shen M, Boxer MB, Hall MD, Sharlow ER, Drew ME, Morris JC.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6023-33. doi: 10.1128/AAC.00914-16. Print 2016 Oct.

15.

Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery.

Merk A, Bartesaghi A, Banerjee S, Falconieri V, Rao P, Davis MI, Pragani R, Boxer MB, Earl LA, Milne JLS, Subramaniam S.

Cell. 2016 Jun 16;165(7):1698-1707. doi: 10.1016/j.cell.2016.05.040. Epub 2016 May 26.

16.

Rem2, a member of the RGK family of small GTPases, is enriched in nuclei of the basal ganglia.

Liput DJ, Lu VB, Davis MI, Puhl HL, Ikeda SR.

Sci Rep. 2016 Apr 27;6:25137. doi: 10.1038/srep25137.

17.

Diaphorase Coupling Protocols for Red-Shifting Dehydrogenase Assays.

Davis MI, Shen M, Simeonov A, Hall MD.

Assay Drug Dev Technol. 2016 Apr;14(3):207-12. doi: 10.1089/adt.2016.706.

18.

Avoiding Fluorescence Assay Interference-The Case for Diaphorase.

Hall MD, Simeonov A, Davis MI.

Assay Drug Dev Technol. 2016 Apr;14(3):175-9. doi: 10.1089/adt.2016.707. Review.

19.

Dopamine dynamics and cocaine sensitivity differ between striosome and matrix compartments of the striatum.

Salinas AG, Davis MI, Lovinger DM, Mateo Y.

Neuropharmacology. 2016 Sep;108:275-83. doi: 10.1016/j.neuropharm.2016.03.049. Epub 2016 Mar 30.

20.

Ubiquitin-Specific Proteases as Druggable Targets.

Davis MI, Simeonov A.

Drug Target Rev. 2015 Fall;2(3):60-64. No abstract available.

21.
23.

Brain BLAQ: Post-hoc thick-section histochemistry for localizing optogenetic constructs in neurons and their distal terminals.

Kupferschmidt DA, Cody PA, Lovinger DM, Davis MI.

Front Neuroanat. 2015 Feb 4;9:6. doi: 10.3389/fnana.2015.00006. eCollection 2015.

24.

Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families.

Rees MG, Raimondo A, Wang J, Ban MR, Davis MI, Barrett A, Ranft J, Jagdhuhn D, Waterstradt R, Baltrusch S, Simeonov A, Collins FS, Hegele RA, Gloyn AL.

Hum Mol Genet. 2014 Oct 15;23(20):5570-8. doi: 10.1093/hmg/ddu269. Epub 2014 May 30.

25.

Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.

Davis MI, Gross S, Shen M, Straley KS, Pragani R, Lea WA, Popovici-Muller J, DeLaBarre B, Artin E, Thorne N, Auld DS, Li Z, Dang L, Boxer MB, Simeonov A.

J Biol Chem. 2014 May 16;289(20):13717-25. doi: 10.1074/jbc.M113.511030. Epub 2014 Mar 25.

26.

A panel of diverse assays to interrogate the interaction between glucokinase and glucokinase regulatory protein, two vital proteins in human disease.

Rees MG, Davis MI, Shen M, Titus S, Raimondo A, Barrett A, Gloyn AL, Collins FS, Simeonov A.

PLoS One. 2014 Feb 19;9(2):e89335. doi: 10.1371/journal.pone.0089335. eCollection 2014.

27.

Chronic methylphenidate exposure during adolescence reduces striatal synaptic responses to ethanol.

Crowley NA, Cody PA, Davis MI, Lovinger DM, Mateo Y.

Eur J Neurosci. 2014 Feb;39(4):548-56. doi: 10.1111/ejn.12426. Epub 2013 Nov 18.

28.

Reply: no support for renal denervation in a meta-analysis.

Davis MI, Filion KB, Eisenberg MJ, Afilalo J, Schiffrin EL, Joyal D.

J Am Coll Cardiol. 2013 Nov 19;62(21):2030. doi: 10.1016/j.jacc.2013.09.009. Epub 2013 Sep 20. No abstract available.

29.

GluN2B in corticostriatal circuits governs choice learning and choice shifting.

Brigman JL, Daut RA, Wright T, Gunduz-Cinar O, Graybeal C, Davis MI, Jiang Z, Saksida LM, Jinde S, Pease M, Bussey TJ, Lovinger DM, Nakazawa K, Holmes A.

Nat Neurosci. 2013 Aug;16(8):1101-10. doi: 10.1038/nn.3457. Epub 2013 Jul 7.

30.

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4398-403. doi: 10.1016/j.bmcl.2013.05.072. Epub 2013 May 29.

31.

Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis.

Davis MI, Filion KB, Zhang D, Eisenberg MJ, Afilalo J, Schiffrin EL, Joyal D.

J Am Coll Cardiol. 2013 Jul 16;62(3):231-241. doi: 10.1016/j.jacc.2013.04.010. Epub 2013 May 1. Review.

32.

[none].

Auld D, Lea W, Davis MI, Simeonov A.

Assay Drug Dev Technol. 2013 Apr;11(3):139-51. doi: 10.1089/adt.2013.1103.lr. No abstract available.

PMID:
23560851
33.

A homogeneous, high-throughput assay for phosphatidylinositol 5-phosphate 4-kinase with a novel, rapid substrate preparation.

Davis MI, Sasaki AT, Shen M, Emerling BM, Thorne N, Michael S, Pragani R, Boxer M, Sumita K, Takeuchi K, Auld DS, Li Z, Cantley LC, Simeonov A.

PLoS One. 2013;8(1):e54127. doi: 10.1371/journal.pone.0054127. Epub 2013 Jan 10.

34.

Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index.

Liu G, Abraham S, Tran L, Vickers TD, Xu S, Hadd MJ, Quiambao S, Holladay MW, Hua H, Ford Pulido JM, Gunawardane RN, Davis MI, Eichelberger SR, Apuy JL, Gitnick D, Gardner MF, James J, Breider MA, Belli B, Armstrong RC, Treiber DK.

J Med Chem. 2012 Apr 12;55(7):3250-60. doi: 10.1021/jm201702g. Epub 2012 Mar 14.

PMID:
22380736
35.

Subsets of Spiny Striosomal Striatal Neurons Revealed in the Gad1-GFP BAC Transgenic Mouse.

Cuzon Carlson VC, Mathur BN, Davis MI, Lovinger DM.

Basal Ganglia. 2011 Nov 1;1(4):201-211.

36.

Comprehensive analysis of kinase inhibitor selectivity.

Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.

Nat Biotechnol. 2011 Oct 30;29(11):1046-51. doi: 10.1038/nbt.1990.

PMID:
22037378
37.

Literature search and review.

Auld D, Lea W, Davis MI, Simeonov A.

Assay Drug Dev Technol. 2011 Jun;9(3):198-212. doi: 10.1089/adt.2011.0903.lr. Review. No abstract available.

PMID:
21612549
38.

Fluorophore assisted light inactivation (FALI) of recombinant 5-HT₃A receptor constitutive internalization and function.

Morton RA, Luo G, Davis MI, Hales TG, Lovinger DM.

Mol Cell Neurosci. 2011 Jun;47(2):79-92. doi: 10.1016/j.mcn.2011.02.007. Epub 2011 Feb 19.

39.

Nr4a1-eGFP is a marker of striosome-matrix architecture, development and activity in the extended striatum.

Davis MI, Puhl HL 3rd.

PLoS One. 2011 Jan 28;6(1):e16619. doi: 10.1371/journal.pone.0016619. Erratum in: PLoS One. 2011;6(2). doi:10.1371/annotation/83671a73-38e3-4ba4-b016-81264138a0ac.

40.

Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP, Treiber DK.

Chem Biol. 2010 Nov 24;17(11):1241-9. doi: 10.1016/j.chembiol.2010.09.010.

41.

Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning.

Brigman JL, Wright T, Talani G, Prasad-Mulcare S, Jinde S, Seabold GK, Mathur P, Davis MI, Bock R, Gustin RM, Colbran RJ, Alvarez VA, Nakazawa K, Delpire E, Lovinger DM, Holmes A.

J Neurosci. 2010 Mar 31;30(13):4590-600. doi: 10.1523/JNEUROSCI.0640-10.2010.

42.

Hydrophobic photolabeling studies identify the lipid-protein interface of the 5-HT3A receptor.

Sanghvi M, Hamouda AK, Davis MI, Morton RA, Srivastava S, Pandhare A, Duddempudi PK, Machu TK, Lovinger DM, Cohen JB, Blanton MP.

Biochemistry. 2009 Oct 6;48(39):9278-86. doi: 10.1021/bi901208j.

43.

The permittivity of thermodynamically ideal liquid mixtures and the excess relative permittivity of binary dielectrics.

Reis JC, Iglesias TP, Douhéret G, Davis MI.

Phys Chem Chem Phys. 2009 May 28;11(20):3977-86. doi: 10.1039/b820613a. Epub 2009 Mar 6.

PMID:
19440627
44.

Latinos and Latinas in communal settings: a grounded theory of recovery.

Alvarez J, Jason LA, Davis MI, Olson BD, Ferrari JR.

Int J Environ Res Public Health. 2009 Apr;6(4):1317-34. doi: 10.3390/ijerph6041317. Epub 2009 Mar 31.

45.

Dynamic reorganization of striatal circuits during the acquisition and consolidation of a skill.

Yin HH, Mulcare SP, Hilário MR, Clouse E, Holloway T, Davis MI, Hansson AC, Lovinger DM, Costa RM.

Nat Neurosci. 2009 Mar;12(3):333-41. doi: 10.1038/nn.2261. Epub 2009 Feb 8.

46.

Oxford House and Alcoholics Anonymous: The Impact of Two Mutual-help Models on Abstinence.

Groh DR, Jason LA, Ferrari JR, Davis MI.

J Groups Addict Recover. 2009 Jan;4(1-2):23-31.

47.

Measuring In-Group and Out-Group Helping in Communal Living: Helping and Substance Abuse Recovery.

Viola JJ, Ferrari JR, Davis MI, Jason LA.

J Groups Addict Recover. 2009 Jan;4(1-2):110-128.

48.

A Longitudinal Analysis of Criminal and Aggressive Behaviors among a National Sample of Adults in Mutual-Help Recovery Homes.

Aase DM, Jason LA, Olson BD, Majer JM, Ferrari JR, Davis MI, Virtue SM.

J Groups Addict Recover. 2009 Jan 1;4(1-2):82-91.

49.

Coming to Terms With Reality: Predictors of Self-deception Within Substance Abuse Recovery.

Ferrari JR, Groh DR, Rulka G, Jason LA, Davis MI.

Addict Disord Their Treat. 2008 Dec 1;7(4):210-218.

50.

The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels.

Godlewski G, Offertáler L, Osei-Hyiaman D, Mo FM, Harvey-White J, Liu J, Davis MI, Zhang L, Razdan RK, Milman G, Pacher P, Mukhopadhyay P, Lovinger DM, Kunos G.

J Pharmacol Exp Ther. 2009 Jan;328(1):351-61. doi: 10.1124/jpet.108.144717. Epub 2008 Oct 15.

Supplemental Content

Loading ...
Support Center